Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bictegravir + emtricitabine + tenofovir alafenamide (Gilead Sciences)
- Development stage
- Phase 4
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Biktarvy is a fixed-dose combination antiretroviral medication indicated for the treatment of HIV-1 infection. It consists of three active components: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is an integrase strand transfer inhibitor (INSTI) that prevents the HIV-1 integrase enzyme from incorporating viral DNA into the host cell genome. Emtricitabine and tenofovir alafenamide are nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), respectively; they function as chain terminators that inhibit the reverse transcription of viral RNA into DNA. This combination is designed as a complete, once-daily oral regimen for both treatment-naive patients and those who are virologically suppressed on a stable antiretroviral regimen. Smits Healthcare distributes this combination, often marketed under the brand name Taffic, which is a generic version of the original Gilead Sciences product.
- Brand names
- BiktarvyTaffic
- Other names
- Taffic Biktarvy TabletsBictegravir/Emtricitabine/Tenofovir Alafenamide
02
Targets
Integrase allosteric pocket (HIV)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on bictegravir + emtricitabine + tenofovir alafenamide (Gilead Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bictegravir + emtricitabine + tenofovir alafenamide (Gilead Sciences).